What happened
Samsung ChatGPT Enterprise deployment is at the center of this update. Samsung Electronics has begun rolling out OpenAI’s ChatGPT Enterprise and Codex to all employees in South Korea and to staff within its Device eXperience (DX) division worldwide. This deployment gives Samsung employees access to advanced conversational AI and AI-assisted coding tools directly from OpenAI.
Why it matters
Samsung’s adoption of these enterprise AI models indicates OpenAI’s expanding influence beyond software-centric companies. By integrating ChatGPT Enterprise and Codex, Samsung is leveraging AI to enhance productivity and innovation in one of the world’s largest electronics manufacturers. This move could accelerate development cycles and improve internal workflows, providing Samsung with a competitive advantage in the evolving AI landscape.
Context
ChatGPT Enterprise offers enhanced security and business-focused features over the consumer ChatGPT, suitable for corporate environments. Codex powers AI-driven code generation and automation, enabling developers to write software more efficiently. Samsung’s DX division, which handles core consumer products like smartphones and wearable devices, stands to benefit from these tools in product design and software development.
Expected impact
The integration is expected to boost Samsung’s internal efficiency and foster AI-enabled innovation throughout its product lines. It may also signal a trend of hardware companies adopting AI enterprise tools, potentially increasing OpenAI’s presence in the device manufacturing sector.
What we still do not know
Details on specific applications, integration depth, and performance metrics for ChatGPT Enterprise and Codex within Samsung remain undisclosed. It is also unclear whether this deployment will lead to deeper collaboration between Samsung and OpenAI going forward.
Related coverage: AI Chronicle analysis and updates.

Google Expands Gemini AI Features in Chrome to India, Canada, and New Zealand
Uber Unveils Spacious Robotaxi Developed with Lucid and Nuro at CES 2026
Converge Bio Secures $25 Million to Accelerate AI-Driven Drug Discovery